Deeper Knowledge, Faster

  • Plan your formulary budget
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
US Department of Justice
Chinese Patent Office
Cantor Fitzgerald
Federal Trade Commission

Generated: June 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,246,980

« Back to Dashboard

Which drugs does patent 8,246,980 protect, and when does it expire?

Patent 8,246,980 protects NEUPRO and is included in one NDA. There has been one Paragraph IV challenge on Neupro.

This patent has twenty-three patent family members in twenty-one countries.

Summary for Patent: 8,246,980

Title:Transdermal delivery system
Abstract: An improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains an amine-functional drug in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of the amine-functional drug and is impermeable to the protonated form of the amine-functional drug.
Inventor(s): Schacht; Dietrich Wilhelm (Koln, DE), Hannay; Mike (Wachtberg-Villiprott, DE), Wolff; Hans-Michael (Monheim, DE)
Assignee: UCB Pharma GmbH (Monheim, DE)
Application Number:10/627,990
Patent Claim Types:
see list of patent claims
Delivery; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ucb Inc
FILM, EXTENDED RELEASE;TRANSDERMAL021829-004Apr 2, 2012RXYesNo8,246,980► SubscribeY
Ucb Inc
FILM, EXTENDED RELEASE;TRANSDERMAL021829-001May 9, 2007RXYesYes8,246,980► SubscribeY
Ucb Inc
FILM, EXTENDED RELEASE;TRANSDERMAL021829-005Apr 2, 2012RXYesNo8,246,980► SubscribeY
Ucb Inc
FILM, EXTENDED RELEASE;TRANSDERMAL021829-002May 9, 2007RXYesNo8,246,980► SubscribeY
Ucb Inc
FILM, EXTENDED RELEASE;TRANSDERMAL021829-003May 9, 2007RXYesNo8,246,980► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,246,980

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
02016864Jul 30, 2002

International Patent Family for Patent: 8,246,980

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand537476► Subscribe
Norway334187► Subscribe
Norway20050770► Subscribe
MexicoPA05000349► Subscribe
South Korea101016914► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus